NCT07204275 Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
| NCT ID | NCT07204275 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Condition | Primary Membranous Nephropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 176 participants |
| Start Date | 2025-09-30 |
| Primary Completion | 2028-12-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 176 participants in total. It began in 2025-09-30 with a primary completion date of 2028-12-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
Eligibility Criteria
Key Inclusion Criteria: • Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility Key Exclusion Criteria: • Hypersensitivity to investigational medicinal product or to any of its excipients Other protocol defined Inclusion/Exclusion criteria will apply
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07204275 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Primary Membranous Nephropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07204275 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07204275 currently recruiting?
Yes, NCT07204275 is actively recruiting participants. Contact the research team at medicalinfo@vrtx.com for enrollment information.
Where is the NCT07204275 trial being conducted?
This trial is being conducted at Montgomery, United States, Surprise, United States, Los Angeles, United States, Tarzana, United States and 11 additional locations.
Who is sponsoring the NCT07204275 clinical trial?
NCT07204275 is sponsored by Vertex Pharmaceuticals Incorporated. The trial plans to enroll 176 participants.